by MyBiosource Editorial Team | Dec 4, 2017 | Uncategorized
Location 2013 2014 2015 Alabama 598 723 736 Alaska 105 124 122 Arizona 1,222 1,211 1,274 Arkansas 319 356 392 California 4,452 4,521 4,659 Colorado 846 899 869 Connecticut 582 623 800 Delaware 166 189 198 District of Columbia 102 96 125 Florida 2,474 2,634 3,228...
by MyBiosource Editorial Team | Dec 4, 2017 | Uncategorized
US States Opiod Prescription Rates, 2011 – 2016, Note: Estimated rate of opioid prescriptions per 100 U.S. residents State 2011 2012 2013 2014 2015 2016 Alabama 136.6 143.8 142.4 135.2 125 121 Alaska 68 66.8 63.7 62.7 60.8 58.9 Arizona 88.6 85.3 80.4 79.7 75.5...
by MyBiosource Editorial Team | Dec 3, 2017 | Uncategorized
Table of Contents I. Introduction II. FDA Commissioner’s Statement III. Mylan and Biocon Collaboration • Overview of the six biologic products developed • Comparison of Ogivri to Roche’s Herceptin IV. Breast Cancer Statistics and Symptoms • Number of breast cancer...
by MyBiosource Editorial Team | Dec 2, 2017 | Uncategorized
Table of Contents I. Introduction II. Yellow fever outbreaks in Nigeria, Angola, and the Democratic Republic of Congo III. Countries at risk of yellow fever IV. Transmission and Symptoms of Yellow Fever V. Prevention and Treatment of Yellow Fever VI. Incubation Time...
by MyBiosource Editorial Team | Dec 2, 2017 | Uncategorized
Table of Contents I. Introduction II. AstraZeneca’s Calquence receives US FDA accelerated approval III. Calquence: a new option for treatment of mantle cell lymphoma IV. Mechanism of action and side effects of Calquence V. FDA priority review and breakthrough...
by MyBiosource Editorial Team | Nov 30, 2017 | Uncategorized
Table of Contents 1. Introduction 2. What is Sly Syndrome? 3. Symptoms of Sly Syndrome 4. Current treatment options 5. Mepsevii: The First FDA-Approved Treatment for Sly Syndrome 6. How Mepsevii Works 7. Safety and Efficacy of Mepsevii 8. Treatment Duration for...
